diabetic retinopathy*
Conditions
Interventions
PDR group:no
RRD/MH group:No
Sponsors
Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the experimental group. 1) confirmed diagnosis of PDR with clear clinical indications for vitrectomy (including retinal detachment affecting the macula, hard-to-resorb vitreous cavity hemorrhage, and Snellen-corrected visual acuity below 20/40). 2) Age 30 years or older. 3) willing to participate in this trial and agree to sign the informed consent form. Control group inclusion criteria. 1) confirmed diagnosis of idiopathic macular fissure or hole-derived retinal detachment, and clinical surgery with vitrectomy treatment indications (complete macular hole combined with posterior vitreous detachment in the central recess, separation of vitreous and macular areas and optic disc, macular total fissure, retinal detachment threatening the macula, combined with unresorbable vitreous cavity hemorrhage, Snellen's corrected visual acuity (less than 20/40). 2) Age 30 years or older. 3) willing to participate in this trial and agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the experimental group. 1) Non-PDR patients. 2) Previous intravitreal injection of any anti-vascular endothelial growth factor drug, history of ocular surgery, or retinal photocoagulation treatment 3) Patients with a history of prior intravitreal injection of any anti-vascular endothelial growth factor drug, ocular surgery, or retinal photocoagulation. 4) poor glycemic control (fasting >8.5 mmol/L or/and postprandial >10 mmol/L) 5) renal failure (plasma creatinine = 120 µM), nephrotic syndrome or laboratory tests for albuminuria and proteinuria. 6) combination of other chronic diseases or serious systemic diseases such as uncontrollable hypertension (diastolic blood pressure >90mmHg or/and systolic systolic blood pressure >150mmHg), severe cardiac insufficiency, cerebrovascular accidents, etc. 7) abnormal coagulation function (aspirin should be discontinued for at least 1 week). 8) Patients with systemic application of immunosuppressants or corticosteroids. 9) Women during pregnancy. 10) Patients assessed by the investigator to be unable to complete the trial or otherwise contraindicated for the procedure. d) Exclusion criteria for the control group. Exclusion criteria for the control group. 1) secondary macular fissure or secondary retinal detachment. 2) Patients with previous intravitreal injection of any anti-vascular endothelial growth factor drug, history of ocular surgery, or history of retinal laser photocoagulation 3) History of previous ocular disease: e.g., patients with keratoconus, glaucoma, dacryocystitis, uveitis, ocular trauma, and age-related macular degeneration. 4) Combined diabetes mellitus. 5) renal failure (plasma creatinine = 120 µM), nephrotic syndrome or laboratory tests for microalbuminuria and proteinuria; and Albuminuria; 6) combination of other chronic diseases or serious systemic diseases such as uncontrollable hypertension (diastolic blood pressure > 90 mmHg or/and systolic blood pressure > 150 mmHg) systolic blood pressure >150mmHg), severe cardiac insufficiency, cerebrovascular accidents, etc. 7) abnormal coagulation (aspirin should be discontinued for at least 1 week). 8) Patients with systemic application of immunosuppressants or corticosteroids. 9) Women during pregnancy. 10) Patients who are assessed by the investigator to be unable to complete the trial or who are otherwise contraindicated for the procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteomics and Metabolomics; | — |
Countries
China
Contacts
Public ContactHanyi Min
Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed